1.Urticaria and Angioedema Associated with Fluoxetine.
Taha Can TUMAN ; Bengü TUMAN ; Mualla POLAT ; Uğur ÇAKIR
Clinical Psychopharmacology and Neuroscience 2017;15(4):418-419
No abstract available.
Angioedema*
;
Fluoxetine*
;
Urticaria*
2.Endoscopic Transnasal Vidian Neurectomy for Intractable Allergic Rhinitis.
Chi Un PAE ; Yeon Joo KIM ; Tae Suk KIM ; Jung Jin KIM ; Chang Uk LEE ; Soo Jung LEE ; Chul LEE ; In Ho PAIK
Journal of Korean Neuropsychiatric Association 2004;43(4):485-488
We hereupon present a case of injured temporomandibular joint (TMJ) associated with fluoxetine monotherapy-induced repeated yawning. Further information is needed regarding the relationship between fluoxetine administration and clinically significant yawning. Clinicians should be more careful to listen to their patients when they describe unexpected reactions to medications.
Fluoxetine
;
Humans
;
Rhinitis*
;
Temporomandibular Joint
;
Yawning
3.Treatment of Obsessive Symptoms in Schizophrenic Patient with a Risperidone-Fluoxetine Combination.
Myong Su CHOI ; Sang Keun CHUNG ; Ik Keun HWANG
Korean Journal of Psychopharmacology 2002;13(1):62-67
Recent studies have reported that obsessive-compulsive (OC) symptoms are highly prevalent in schizophrenia, and schizophrenic patients with OC symptoms have a poorer clinical course compared to those without OC symptoms. In spite of many previous case reports, treatment of OC symptoms in schizophrenia has not been systematically studied. We report a patient with chronic schizophrenia who had obsessive symptoms such as bizarre, stereotyped behaviors. Treatment with olanzapine and risperidone, resulted in partial response for his psychotic symptoms, respectively. The obsessive symptoms, however, persisted and fluoxetine was added to the risperidone regimen. After 4 weeks of combination treatment, fluoxetine was titrated up to 80 mg/day and his obsessive symptoms became less in frequency and intensity. After 7 weeks on combination treatment of risperidone and fluoxetine, obsessive symptoms resulted in a significant reduction. On the 20 months of following, he remained in a recovered state and had been treated with risperidone 4 mg/day, and fluoxetine 20 mg/day.
Fluoxetine
;
Humans
;
Risperidone
;
Schizophrenia
;
Stereotyped Behavior
4.Changes of Psychopathology and Extrapyramidal Symptoms When Co-administering Fluoxetine and Haloperidol.
Min Soo LEE ; Chang Su HAN ; Jae Won KIM ; Kyung Sik WON ; Dong ll KWAK
Journal of the Korean Society of Biological Psychiatry 1997;4(1):121-126
OBJECTIVES: The authors have intended to know the drug interaction of fluoxetine and haloperidol when coadministering two drugs to the chronic schizophrenics by assessing the changes of positive, negative symptoms and extrapyramidal symptoms. METHOD: We selected 38 patients, the chronic schizophrenics with no physical problems. they are randomly assigned to placebo group and drug group. And then, placebo or fluoxetine 20mg were administered to the subjects of each group during 8 week period. We have assessed their psychopathology and extrapyramidal symptoms using positive and Negative Syndrome Scale(PANSS), Clinical Global Impression(CGI), Simpson-Angus Scale at o, 2, 4, 6, 8 week during the period. RESULTS: 38 patients have completed the study during 8 week. 1) PANSS, CGI : no significant difference between groups and no significant change according to the times. 2) Simpson-Angus Scale : no significant changes. CONCLUSION: When co-administering fluoxetine and haloperidol, there were no significant changes of psychopathology and extrapyramidal symptoms. There results suggest that it is safe to coadminister fluoxetine to schizophrenic with haloperidol treatment.
Drug Interactions
;
Fluoxetine*
;
Haloperidol*
;
Humans
;
Psychopathology*
5.A Data Warehouse Based Retrospective Post-marketing Surveillance Method: A Feasibility Test with Fluoxetine.
Man Young PARK ; Young Ho LEE ; Eun Yeob KIM ; Woo Jae KIM ; Hye Jin KAM ; Jong Pill CHOI ; Tae Hwa HAN ; Un Gu KANG ; Rae Woong PARK
Journal of Korean Society of Medical Informatics 2009;15(2):191-199
OBJECTIVE: Post-marketing surveillance (PMS) is an adverse events monitoring practice of pharmaceutical drugs on the market. Traditional PMS methods are labor intensive and expensive to perform, because they are largely based on manual work including phone-calling, mailing, or direct visits to relevant subjects. The objective of this study was to develop and validate a PMS methodology based on the clinical data warehouse (CDW). METHODS: We constructed a archival DB using a hospital information system and a refined CDW from three different hospitals. Fluoxetine hydrochloride, an antidepressant, was selected as the target monitoring drug. Corrected QT prolongation on ECG was selected as the target adverse outcome. The Wilcoxon signed rank test was performed to analyze the difference in the corrected QT interval before and after the target drug administration. RESULTS: A refined CDW was successfully constructed from three different hospitals. Table specifications and an entity-relation diagram were developed and are presented. A total of 13 subjects were selected for monitoring. There was no statistically significant difference in the QT interval before and after target drug administration (p=0.727). CONCLUSION: The PMS method based on CDW was successfully performed on the target drug. This IT-based alternative surveillance method might be beneficial in the PMS environment of the future.
Electrocardiography
;
Fluoxetine
;
Hospital Information Systems
;
Postal Service
;
Retrospective Studies
6.There Cases of Extrapyramidal Symptoms Following Fluoxetine.
Min NAM ; In Kwa JUNG ; Dong ll KWAK ; Gi Chul LEE ; Jung Ho LEE
Journal of Korean Neuropsychiatric Association 1997;36(2):376-383
The selective serotonin reuptake inhibitor fluoxetine is one of the most frequently prescribed drugs for the treatment of depression and other psychiatric disorders. In the few years, there have been several reports of adverse effects encountered during coadministration of fluoxetine with or without other psychotropic drugs. We experienced three cases of extrapyamidal symptoms were developed when administered fluoxetine alone and with neuroleptics. We conclude that there is a probable or possible causal relationship between fluoxetine and extrapyramidal side effects. The pathogenesis of such adverse reactions, which may be hetero-geneous, is unknown, but it has been suggested that they might be caused by serotonergically mediated inhibition of dopaminergic transmission. From reports in those cases, it appears that fluoxetine alone may be associated with extrapyramidal side reactions. Furthermore the potential for increased levels of concomitant psychotropic medicines and increased side effects, should be borne in mind.
Antipsychotic Agents
;
Depression
;
Fluoxetine*
;
Psychomotor Agitation
;
Psychotropic Drugs
;
Serotonin
7.Stereoisomerism(Chirality) of Psychotropic Drugs.
Korean Journal of Psychopharmacology 2003;14(1):3-10
Many psychotropic drugs are marketed and prescribed as a racemate form in a mixture of the stereoisomers. A chiral center or a center of unsaturation of carbon atoms in the chemical structures creates various stereoisomers of the psychotropic drugs, including antidepressants such as fluoxetine and venlafaxine, etc. The stereochemical significances of enantiomers on the pharmacokinetics and pharmacodynamics of several psychotropic drugs and their relationships with pharmacogenetic polymorphisms were reviewed. The single enantiomer drugs will be increasing more in the market shares replacing the racemic drugs by chiral switching, which is driven by the development of the analytical and preparative resolution techniques and will be of much benefit to the treatment from low dosages, simple dose-response curve, few adverse reactions, and so on.
Antidepressive Agents
;
Carbon
;
Fluoxetine
;
Pharmacokinetics
;
Psychotropic Drugs*
;
Stereoisomerism
;
Venlafaxine Hydrochloride
8.CREB-Phosphorylation as a Predictor of Therapeutic Response to Antidepressants.
Yu Jin LEE ; Shinn Won LIM ; Soo Yeon KIM ; Jae Won JUNG ; Jin Woo KIM ; Woo Jae MYUNG ; Ji Hye SONG ; Doh Kwan KIM
Journal of Korean Geriatric Psychiatry 2010;14(1):38-43
OBJECTIVES: CREB (c-AMP response element binding protein) is known as a key mediator of the therapeutic response to antidepressants. We investigated the change of CREB-phosphorylation (pCREB) at the early point of the fluoxetine treatment to find out it can be a predictor for antidepressant response. METHODS: We evaluated the pCREB of T - lymphocyte nuclear extracts from 18 depressed patients at 0 and 1th week during fluoxetine treatment (20 mg/day). Responders were defined as the > or = 50% reduction of HAM-D score in 4 weeks. We compared the changes of pCREB at 0 and 1th week between responders and non-responders. RESULTS: The responders showed a significant increase of pCREB at week 1 compared with week 0. The HAM-D difference between week 0 and 4 was positively correlated with the change of pCREB response. CONCLUSION: These results suggest that the early change of pCREB in peripheral lymphocyte can predict the later response of antidepressant. The correlation showed pCREB directly reflects a response status to the antidepressant fluoxetine and clinical improvement.
Antidepressive Agents
;
Depression
;
Fluoxetine
;
Humans
;
Lymphocytes
;
Response Elements
9.CREB-Phosphorylation as a Predictor of Therapeutic Response to Antidepressants.
Yu Jin LEE ; Shinn Won LIM ; Soo Yeon KIM ; Jae Won JUNG ; Jin Woo KIM ; Woo Jae MYUNG ; Ji Hye SONG ; Doh Kwan KIM
Journal of Korean Geriatric Psychiatry 2010;14(1):38-43
OBJECTIVES: CREB (c-AMP response element binding protein) is known as a key mediator of the therapeutic response to antidepressants. We investigated the change of CREB-phosphorylation (pCREB) at the early point of the fluoxetine treatment to find out it can be a predictor for antidepressant response. METHODS: We evaluated the pCREB of T - lymphocyte nuclear extracts from 18 depressed patients at 0 and 1th week during fluoxetine treatment (20 mg/day). Responders were defined as the > or = 50% reduction of HAM-D score in 4 weeks. We compared the changes of pCREB at 0 and 1th week between responders and non-responders. RESULTS: The responders showed a significant increase of pCREB at week 1 compared with week 0. The HAM-D difference between week 0 and 4 was positively correlated with the change of pCREB response. CONCLUSION: These results suggest that the early change of pCREB in peripheral lymphocyte can predict the later response of antidepressant. The correlation showed pCREB directly reflects a response status to the antidepressant fluoxetine and clinical improvement.
Antidepressive Agents
;
Depression
;
Fluoxetine
;
Humans
;
Lymphocytes
;
Response Elements
10.A Case of Fluoxetine Induced Mania in Poststroke Depression Patient: A case report.
Ye Rim CHO ; Hye Won KIM ; Jong In LEE ; Jong Soo YUN ; Jung Soo LEE ; Young Seop WOO
Journal of the Korean Academy of Rehabilitation Medicine 2008;32(1):116-118
Poststroke depression is very common and has been reported in as many as 40~50% of poststroke patients. The fluoxetine is one of the most frequently prescribed drugs for the treatment of poststroke depression. This serotonin selective reuptake inhibitor, known as generally safe and well tolerated drug, has been recently reported to induce mania. We report a case of fluoxetine-induced mania. A 64 year-old male, who has taken 10 mg of fluoxetine daily due to poststroke depression, presented elevated mood, hyperactivity, regressed behavior, excessive planning, sleep deterioration, and talkativeness abruptly. We were suspicious of fluoxetine- induced manic state and discontinued immediately fluoxetine without prescription of mood stabilizer. His symptoms had been ceased over two weeks.
Bipolar Disorder
;
Depression
;
Fluoxetine
;
Humans
;
Male
;
Prescriptions
;
Serotonin